A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

Diabetes, Obesity and Metabolism

Volumn 18, Issue , 2016, Pages 25-33

  Garg, Satish ^a   Dreyer, M ^b   Jinnouchi, H ^c   Mou, J ^d   Qu, Y ^d   Hartman, M L ^d   Rosilio, M ^d   Jacober, S J ^d   Bastyr, E J ^d,e  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b Mingci Cardiovascular Disease Hospital   (China)

^c Jinnouchi Hospital   (Japan)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basal insulin; glycaemic control; hypoglycaemia; randomised trial; type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; MACROGOL DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE ABSCESS; INJECTION SITE ABSCESS STERILE; INJECTION SITE ATROPHY; INJECTION SITE EDEMA; INJECTION SITE HYPERTROPHY; INJECTION SITE INDURATION; INJECTION SITE MASS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; MEAL; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN GLARGINE; INSULIN LISPRO; MALE; MEALS; MIDDLE AGED; POLYETHYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84990202423     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12738     Document Type: Article

References (26)

1. Sinha VP, Choi SL, Soon DK, et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol. 2014;54:792–799.
2. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:344–350.
3. Knadler MP, Nguyen T-H, Campanale KM, et al. Lymphatic absorption of basal insulin peglispro (BIL) in Sheep. Diabetes. 2015;64:A262.
4. Henry RR, Mudaliar S, Ciaraldi TP, et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014;37:2609–2615.
5. Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63:494–504.
6. Mudaliar S, Henry RR, Ciaraldi TP, et al. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM). Diabetes. 2015;64:LB22–LB23.
7. Morrow LA, Hompesch M, Jacober SJ, et al. Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial. Diabetes Obes Metab. 2016;18:1064–1070.
8. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–528.
9. Bergenstal RM, Lunt H, Franek E, et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1080–1087.
10. Bastyr EJ III, Zhang S, Mou J, et al. Performance of an electronic diary system for intensive insulin management in global diabetes clinical trials. Diabetes Technol Ther. 2015;17:571–579.
11. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J. 2008;50:667–677.
12. Luo J, Jacober SJ, Prince MJ, Carey MA, Qu Y. The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials. Diabetes Technol Ther. 2013;15:654–661.
13. Luo J, Qu Y. Analysis of hypoglycemic events using negative binomial models. Pharm Stat. 2013;12:233–242.
14. Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat. 2015;14:56–62.
15. Drug AdministrationU.S.Center for Drug Evaluation and Research, Food and Department of Health and Human Services. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation: 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed June 28, 2016.
16. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819–828.
17. Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes. 1992;41:255–260.
18. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–453.
19. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104:106–110.
20. Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2001;109:393–396.
21. Davies MJ, Russel-Jones D, Selam JL, et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18:1054–1063.
22. Chaudhuri A, Rosenstock J, DiGenio A, et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev. 2012;28:258–267.
23. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23:736–742.
24. Au JS, Navarro VJ, Rossi S. Review article: drug-induced liver injury—its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther. 2011;34:11–20.
25. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–739.
26. Cusi K, Sanyal A, Zhang S, et al. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab. 2016;18(Suppl 2):50–58.